Healthcare Jan 26, 2022 04:44 PM (GMT+8) · EqualOcean
On January 25, Johnson & Johnson announced its performance in 2021, which is also the first multinational pharmaceutical enterprise in the world to announce its performance in 2021. Johnson & Johnson achieved a total revenue of US $93.775 billion, a year-on-year increase of 13.6%; Among them, the revenue from pharmaceutical business was USD 52.08 billion (+ 14.3%), the revenue from medical device business was USD 27.06 billion (+ 17.9%), and the revenue from consumer health business was USD 14.635 billion (+ 4.1%). The annual R & D investment was US $14.714 billion, a year-on-year increase of 21%. It can be seen from the performance that the pharmaceutical business and medical device business are the strong driving factors to promote the double-digit growth of Johnson & Johnson's performance. The strong growth of pharmaceutical business is mainly driven by several products such as stellara, darzalex, imbruvica, tremfya and erleda. In addition, covid-19 vaccine (ad26. Cov2. S) also contributed $2.385 billion in sales revenue.

This text is a result of machine translation.